Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:3498 |
| Name | pancreatic ductal adenocarcinoma |
| Definition | A pancreatic adenocarcinoma that derives_from pancreatic duct cells. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Xrefs |
SNOMEDCT_US_2023_03_01:792907004
|
| Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer pancreatic carcinoma pancreatic adenocarcinoma pancreatic ductal adenocarcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| BRAF N486_P490del | Trametinib | pancreatic ductal adenocarcinoma | sensitive | detail... |
| ATM R3008C | Fluorouracil + Oxaliplatin + Veliparib | pancreatic ductal adenocarcinoma | no benefit | detail... |
| ATM T2333Nfs*40 | Fluorouracil + Oxaliplatin + Veliparib | pancreatic ductal adenocarcinoma | no benefit | detail... |
| BRAF N486_P490del | LY3009120 | pancreatic ductal adenocarcinoma | predicted - sensitive | detail... |
| BRAF N486_P490del | LY3009120 + Trametinib | pancreatic ductal adenocarcinoma | sensitive | detail... |
| BRAF V600E | Cobimetinib + Gemcitabine + Nab-paclitaxel | pancreatic ductal adenocarcinoma | predicted - sensitive | detail... |
| BRAF V600E | Trametinib + Vemurafenib | pancreatic ductal adenocarcinoma | predicted - sensitive | detail... |
| BRAF V600E | Dabrafenib + Trametinib | pancreatic ductal adenocarcinoma | predicted - sensitive | detail... |
| BRAF V600E | Cobimetinib + Vemurafenib | pancreatic ductal adenocarcinoma | predicted - sensitive | detail... |
| BRAF V600E | Ulixertinib | pancreatic ductal adenocarcinoma | predicted - sensitive | detail... |
| FGFR2 rearrange | Erdafitinib | pancreatic ductal adenocarcinoma | predicted - sensitive | detail... |
| BRAF N486_P490del | Dabrafenib + Trametinib | pancreatic ductal adenocarcinoma | predicted - sensitive | detail... |
| BRAF N486_P490del | Ulixertinib | pancreatic ductal adenocarcinoma | sensitive | detail... |
| BRAF N486_P490del | Binimetinib | pancreatic ductal adenocarcinoma | sensitive | detail... |
| BRAF N486_P490del | SCH772984 | pancreatic ductal adenocarcinoma | sensitive | detail... |
| BRAF N486_P490del | Sorafenib | pancreatic ductal adenocarcinoma | sensitive | detail... |
| BRAF N486_P490del | LXH 254 | pancreatic ductal adenocarcinoma | sensitive | detail... |
| ARID1A Q1327* | Olaparib | pancreatic ductal adenocarcinoma | predicted - sensitive | detail... |
| BRAF V600E | Binimetinib + Cetuximab + Encorafenib | pancreatic ductal adenocarcinoma | predicted - sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01647828 | Phase Ib/II | Nab-paclitaxel Gemcitabine Tarextumab | A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer | Completed | USA | 0 |
| NCT02042378 | Phase II | Rucaparib | A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation | Completed | USA | ISR | 0 |
| NCT02101021 | Phase II | Gemcitabine + Nab-paclitaxel Momelotinib | Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma | Terminated | USA | 0 |
| NCT02109445 | Phase II | Gemcitabine + Nab-paclitaxel Nirogacestat | Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies | Terminated | USA | 0 |
| NCT02241187 | Phase I | Cetuximab + PEGPH20 | Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection | Completed | USA | 0 |
| NCT02259114 | Phase I | Birabresib | A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors | Completed | 0 | |
| NCT02289898 | Phase II | Demcizumab + Gemcitabine + Nab-paclitaxel | Study of Gemcitabine, Abraxane Plus Placebo Versus Gemcitabine, Abraxane Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma | Completed | USA | GBR | ESP | CAN | BEL | AUS | 0 |
| NCT02362048 | Phase II | Acalabrutinib Pembrolizumab | ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer | Completed | USA | 0 |
| NCT02501902 | Phase I | Nab-paclitaxel + Palbociclib | Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC | Completed | USA | ESP | 0 |
| NCT02559492 | Phase I | Epacadostat + Itacitinib Itacitinib + Parsaclisib | INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors | Terminated | USA | 0 |
| NCT02583477 | Phase Ib/II | AZD5069 + Durvalumab Durvalumab + Gemcitabine + Nab-paclitaxel | Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma | Completed | USA | GBR | 0 |
| NCT02600949 | Phase I | Imiquimod + Pembrolizumab Imiquimod + Pembrolizumab + Sotigalimab Pembrolizumab Imiquimod | Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer | Active, not recruiting | USA | 0 |
| NCT02672917 | Phase I | MVT-5873 | Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies | Terminated | USA | 0 |
| NCT02705196 | Phase Ib/II | Atezolizumab + Gemcitabine + LOAd703 + Nab-paclitaxel Gemcitabine + LOAd703 + Nab-paclitaxel | LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer | Completed | USA | 0 |
| NCT02732938 | Phase I | Gemcitabine + Nab-paclitaxel + PF-04136309 | Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (CCR2i) | Terminated | USA | 0 |
| NCT02754726 | Phase II | Cisplatin + Gemcitabine + Nab-paclitaxel + Nivolumab + Paricalcitol | Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma | Completed | USA | 0 |
| NCT02810418 | Phase Ib/II | LMB-100 LMB-100 + Nab-paclitaxel | Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors | Completed | USA | 0 |
| NCT02857270 | Phase I | LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | Completed | USA | FRA | AUS | 1 |
| NCT02879318 | Phase II | Gemcitabine + Nab-paclitaxel Durvalumab + Tremelimumab | Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Pancreatic Adenocarcinoma | Completed | CAN | 0 |
| NCT02880371 | Phase Ib/II | ARRY-382 + Pembrolizumab | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | Terminated | USA | 0 |
| NCT02921022 | Phase 0 | Gemcitabine + Nab-paclitaxel + PEGPH20 | Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma | Active, not recruiting | USA | 0 |
| NCT02942095 | Phase I | Erlotinib + Ixazomib | Study of Ixazomib and Erlotinib in Solid Tumors | Completed | USA | 0 |
| NCT02978547 | Phase II | Metformin | The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma (Metformin 001) | Unknown status | CAN | 0 |
| NCT02981342 | Phase II | Capecitabine Abemaciclib Gemcitabine Abemaciclib + LY3023414 Abemaciclib + Galunisertib | A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | Completed | USA | ISR | GBR | FRA | ESP | BEL | AUS | 1 |
| NCT02993731 | Phase III | Gemcitabine + Nab-paclitaxel + Napabucasin Gemcitabine + Nab-paclitaxel | A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P) | Completed | USA | POL | NLD | ITA | FRA | ESP | DEU | CZE | CAN | BEL | AUT | AUS | 8 |
| NCT03038477 | Phase II | Durvalumab | A Study of Durvalumab in Patients With Borderline Resectable Pancreas Adenocarcinoma Following Neoadjuvant Therapy and Successful Surgical Resection | Withdrawn | USA | 0 |
| NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |
| NCT03118349 | Phase I | MVT-1075 + MVT-5873 | Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy | Terminated | USA | 0 |
| NCT03193190 | Phase Ib/II | Atezolizumab + BKT140 Fluorouracil + Gemcitabine + Leucovorin + Nab-paclitaxel + Oxaliplatin + Pembrolizumab Atezolizumab + PEGPH20 Atezolizumab + Cobimetinib | A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Completed | USA | ESP | DEU | 2 |
| NCT03264404 | Phase II | Azacitidine + Pembrolizumab | Azacitidine and Pembrolizumab in Pancreatic Cancer | Completed | USA | 0 |
| NCT03313778 | Phase I | Intismeran autogene + Pembrolizumab Intismeran autogene | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603) | Active, not recruiting | USA | GBR | AUS | 1 |
| NCT03412799 | Phase I | Gemcitabine + Nab-paclitaxel + SBP-101 | Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer | Completed | USA | AUS | 0 |
| NCT03415126 | Phase I | ERAS-007 | A Study of ASN007 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
| NCT03415854 | Phase II | Cisplatin + Gemcitabine + Nab-paclitaxel + Paricalcitol | Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) (NABPLAGEMD) | Completed | USA | 0 |
| NCT03425279 | Phase Ib/II | Mecbotamab Vedotin | CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors | Completed | USA | 2 |
| NCT03432676 | Phase II | Epacadostat + Pembrolizumab | Study of IDO-1 Inhibitor Epacadostat in Combination With Pembrolizumab in Advanced Pancreatic Cancer With Chromosomal Instability/ Homologous Recombination Repair Deficiency (HRD) | Withdrawn | 0 | |
| NCT03435250 | Phase I | AG-270 + Docetaxel AG-270 + Gemcitabine + Nab-paclitaxel AG-270 | Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss | Terminated | USA | FRA | ESP | 0 |
| NCT03450018 | Phase Ib/II | Gemcitabine + SLC-0111 | A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX (SLC-0111-17-01) | Terminated | CAN | 0 |
| NCT03496662 | Phase Ib/II | Nivolumab BMS-813160 + Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel BMS-813160 + Gemcitabine + Nab-paclitaxel + Nivolumab | BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) | Completed | USA | 0 |
| NCT03592888 | Phase I | mDC3/8-KRAS vaccine | DC Vaccine in Pancreatic Cancer | Completed | USA | 0 |
| NCT03608631 | Phase I | iExosomes | IExosomes in Treating Participants with Metastatic Pancreas Cancer with KrasG12D Mutation | Recruiting | USA | 0 |
| NCT03610490 | Phase II | Aldesleukin + Cyclophosphamide + Fludarabine + MDA autologous tumor-infiltrating lymphocytes | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma | Terminated | USA | 0 |
| NCT03634332 | Phase II | PEGPH20 + Pembrolizumab | Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC | Unknown status | USA | 0 |
| NCT03637491 | Phase II | Avelumab + Binimetinib + Talazoparib Avelumab + Binimetinib | A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors | Terminated | USA | BEL | 1 |
| NCT03681951 | Phase Ib/II | GSK3145095 GSK3145095 + Pembrolizumab | First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors | Terminated | USA | 0 |
| NCT03682289 | Phase II | Ceralasertib + Olaparib Olaparib | Phase II Trial of AZD6738 Alone and in Combination With Olaparib | Recruiting | USA | 0 |
| NCT03727880 | Phase II | Defactinib + Pembrolizumab Pembrolizumab | Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | Completed | USA | 0 |
| NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Completed | USA | NLD | GBR | FRA | FIN | ESP | 0 |
| NCT03806309 | Phase II | OSE 2101 Nivolumab + OSE 2101 Fluorouracil + Irinotecan + Leucovorin | OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC (TEDOPAM) | Active, not recruiting | FRA | 0 |
| NCT03811652 | Phase I | MEDI7247 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | Completed | USA | CAN | 0 |
| NCT03871959 | Phase I | Pembrolizumab + Xevinapant | Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma (CATRIPCA) | Completed | FRA | 0 |
| NCT03953235 | Phase Ib/II | GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | Completed | USA | 0 |
| NCT03979066 | Phase II | Atezolizumab Atezolizumab + PEGPH20 | Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma (NEOiPANC) | Terminated | USA | 0 |
| NCT04042480 | Phase I | SGN-CD228A | A Study of SGN-CD228A in Advanced Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | 0 |
| NCT04111172 | Phase II | Ad5.F35-hGCC-PADRE | Phase 2A Study of Ad5.F35-hGCC-PADRE in Gastrointestinal Malignancies | Active, not recruiting | USA | 0 |
| NCT04117958 | Phase I | AMG 199 | Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers | Terminated | USA | NLD | FRA | ESP | DEU | AUT | 3 |
| NCT04161755 | Phase I | Atezolizumab + Autogene cevumeran + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery | Active, not recruiting | USA | 0 |
| NCT04229004 | Phase III | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Gemcitabine + Nab-paclitaxel | A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer | Completed | USA | 0 |
| NCT04243499 | Phase I | ICT01 | First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) | Active, not recruiting | USA | GBR | FRA | ESP | DEU | BEL | 0 |
| NCT04257448 | Phase Ib/II | Gemcitabine + Nab-paclitaxel + Romidepsin Azacitidine + Gemcitabine + Nab-paclitaxel Azacitidine + Gemcitabine + Nab-paclitaxel + Romidepsin Gemcitabine + Nab-paclitaxel Durvalumab + Lenalidomide | Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer (SEPION) | Completed | DEU | 0 |
| NCT04262388 | Phase II | Durvalumab + Oleclumab | A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME) | Withdrawn | CAN | 0 |
| NCT04338685 | Phase I | RO7119929 + Tocilizumab | A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases | Completed | USA | ESP | DNK | 3 |
| NCT04431258 | Phase Ib/II | Fluorouracil + Ibrilatazar + Irinotecan + Oxaliplatin Fluorouracil + Irinotecan + Oxaliplatin | ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study (PanC-ASAP) | Completed | USA | ISR | FRA | ESP | 0 |
| NCT04477343 | Phase I | Nivolumab + SX-682 | A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | Recruiting | USA | 0 |
| NCT04493060 | Phase II | Dostarlimab-gxly + Niraparib | Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer | Completed | USA | 0 |
| NCT04536077 | Phase II | CDX-1140 + CDX-301 CDX-1140 | Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients | Terminated | USA | 0 |
| NCT04581343 | Phase I | Canakinumab + Gemcitabine + Nab-paclitaxel + Spartalizumab | A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients (PanCAN-SR1) | Completed | USA | 0 |
| NCT04657068 | Phase Ib/II | ART0380 + Gemcitabine ART0380 + Irinotecan ART0380 Gemcitabine | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | Recruiting | USA | GBR | FRA | ESP | 0 |
| NCT04659603 | Phase II | SAR408701 Gemcitabine + SAR408701 | Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors (CARMEN-BT01) | Terminated | USA | TUR | NLD | HUN | ESP | ARG | 4 |
| NCT04672434 | Phase I | Sym021 + Sym024 Sym024 | Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies | Completed | USA | CAN | 0 |
| NCT04704154 | Phase II | Nivolumab + Regorafenib | A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | Completed | USA | ITA | GBR | FRA | BEL | 3 |
| NCT04752696 | Phase II | Fluorouracil + Leucovorin + Liposomal irinotecan + Onvansertib | Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma | Completed | USA | 0 |
| NCT04753879 | Phase II | Olaparib + Pembrolizumab Capecitabine + Cisplatin + Gemcitabine + Irinotecan + Nab-paclitaxel | Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | Recruiting | USA | 0 |
| NCT04809766 | Phase I | Bendamustine FH-TCR-TMSLN Cyclophosphamide + Fludarabine | Mesothelin-Specific T-Cells (FH-TCR-TMSLN) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | Terminated | USA | 0 |
| NCT04853017 | Phase Ib/II | ELI-002 | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201) | Completed | USA | 0 |
| NCT04887805 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer | Recruiting | USA | 0 |
| NCT04888312 | Phase Ib/II | Fluorouracil + Irinotecan + JNJ-64457107 + Leucovorin + Oxaliplatin | Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients (OPTIMIZE-1) | Active, not recruiting | FRA | ESP | BEL | 0 |
| NCT04900818 | Phase I | Givastomig Givastomig + Nivolumab Durvalumab + Givastomig | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | Recruiting | USA | 1 |
| NCT04907851 | Phase II | Denosumab + RXC004 Denosumab + Pembrolizumab + RXC004 | A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (KEYNOTE-E86) | Completed | GBR | AUS | 0 |
| NCT04916236 | Phase I | LY3214996 + RMC-4630 | Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA) | Terminated | NLD | 0 |
| NCT04935359 | Phase III | Gemcitabine + Nab-paclitaxel + NIS793 Gemcitabine + Nab-paclitaxel | Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 | Completed | USA | TUR | SWE | SVK | NOR | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUS | 6 |
| NCT04939610 | Phase Ib/II | 177Lu-FAP-2286 | A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE) | Recruiting | USA | ITA | FRA | ESP | CAN | AUS | 0 |
| NCT04943900 | Phase I | BMS-986416 + Nivolumab BMS-986416 | A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | Completed | USA | NLD | CAN | BEL | ARG | 2 |
| NCT04975217 | Phase I | Fecal microbiota | Fecal Microbial Transplants for the Treatment of Pancreatic Cancer | Recruiting | USA | 0 |
| NCT04976634 | Phase II | Belzutifan + Lenvatinib + Pembrolizumab | Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) | Active, not recruiting | USA | NZL | NLD | ISR | FRA | ESP | BEL | AUS | 2 |
| NCT04989387 | Phase I | INCA00186 + Retifanlimab INCA00186 + INCB106385 INCA00186 + INCB106385 + Retifanlimab INCA00186 | Study of INCA 0186 in Subjects With Advanced Solid Tumors | Terminated | USA | NLD | GBR | ESP | BEL | AUT | 0 |
| NCT04990037 | Phase I | Fluorouracil + Irinotecan + Leucovorin + Nidanilimab + Oxaliplatin | A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma (CAPAFOUR) | Completed | FRA | ESP | 0 |
| NCT05031494 | Phase II | Toripalimab-tpzi + YH003 Gemcitabine + Nab-paclitaxel + Toripalimab-tpzi + YH003 | A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers | Completed | USA | AUS | 0 |
| NCT05042128 | Phase II | Gemcitabine + Nab-paclitaxel CEND-1 + Gemcitabine + Nab-paclitaxel | The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (ASCEND) | Active, not recruiting | NZL | AUS | 0 |
| NCT05052723 | Phase II | Cabozantinib + Pembrolizumab | Cabozantinib and Pembrolizumab in Metastatic Pancreas | Completed | USA | 0 |
| NCT05055323 | Phase I | Pyrvinium | A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer | Active, not recruiting | USA | 0 |
| NCT05074472 | Phase Ib/II | ZB131 | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors | Completed | USA | 0 |
| NCT05093231 | Phase II | Olaparib + Pembrolizumab | Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer | Recruiting | GBR | 0 |
| NCT05121038 | Phase Ib/II | CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab | CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab (CENDIFOX) | Active, not recruiting | USA | 0 |
| NCT05254171 | Phase II | Gemcitabine + Nab-paclitaxel + SBP-101 Gemcitabine + Nab-paclitaxel | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer (ASPIRE) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS | 1 |
| NCT05298592 | Phase I | BMS-986406 + Nivolumab BMS-986406 | A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | Completed | USA | ESP | BEL | ARG | 2 |
| NCT05307874 | Phase Ib/II | Aldesleukin + ICT01 | Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors (EVICTION-2) | Completed | GBR | FRA | DEU | 0 |
| NCT05325866 | Phase I | Bemarituzumab | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301) | Completed | USA | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 4 |
| NCT05382559 | Phase I | ASP3082 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin ASP3082 ASP3082 + Docetaxel ASP3082 + Pembrolizumab ASP3082 + Cisplatin + Pemetrexed Disodium ASP3082 + Gemcitabine + Nab-paclitaxel ASP3082 + Carboplatin + Pemetrexed Disodium ASP3082 + Cisplatin + Pembrolizumab + Pemetrexed Disodium ASP3082 + Cetuximab ASP3082 + Carboplatin + Pembrolizumab + Pemetrexed Disodium | A Study of ASP3082 in Adults With Advanced Solid Tumors | Recruiting | USA | FRA | ESP | 4 |
| NCT05442749 | Phase II | Niraparib | Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer (PARPi-PANC) | Terminated | FRA | 0 |
| NCT05458219 | Phase I | Fluorouracil + IBI343 + Leucovorin + Oxaliplatin Fluorouracil + IBI343 + Irinotecan + Leucovorin + Oxaliplatin IBI343 | A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | Recruiting | USA | AUS | 1 |
| NCT05482893 | Phase Ib/II | Spevatamig | Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) | Recruiting | USA | 0 |
| NCT05494866 | Phase I | Cobicistat + Gemcitabine + Nab-paclitaxel | A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients With Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma (IntenSify) | Terminated | DEU | 0 |
| NCT05498597 | Phase I | AMT-151 | AMT-151 in Patients With Selected Advanced Solid Tumours | Unknown status | AUS | 1 |
| NCT05512377 | Phase II | BI 907828 | Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder | Completed | USA | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS | 7 |
| NCT05539430 | Phase I | LB1908 | Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma | Active, not recruiting | USA | 0 |
| NCT05546853 | Phase I | Fluorouracil + Irinotecan + Leucovorin + NP137 + Oxaliplatin | Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma (LAP-NET1) | Completed | FRA | 0 |
| NCT05547321 | Phase I | OMTX705 + Pembrolizumab OMTX705 + Tislelizumab OMTX705 | Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors. | Recruiting | USA | ESP | 0 |
| NCT05558982 | Phase II | Pembrolizumab + Talabostat mesylate | BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (EXPEL PANC) | Active, not recruiting | USA | 0 |
| NCT05585320 | Phase Ib/II | IMM-1-104 Dabrafenib + IMM-1-104 IMM-1-104 + Pembrolizumab Gemcitabine + IMM-1-104 + Nab-paclitaxel Fluorouracil + IMM-1-104 + Irinotecan + Leucovorin + Oxaliplatin | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |
| NCT05605509 | Phase II | Fluorouracil + Irinotecan + Leucovorin + RP-6306 RP-3500 + RP-6306 RP-6306 + Trastuzumab Gemcitabine + RP-6306 | RP-6306 in Patients With Advanced Cancer | Completed | CAN | 0 |
| NCT05605522 | Phase I | 225Ac-FPI-2059 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | Terminated | USA | AUS | 0 |
| NCT05607953 | Phase I | Nelitolimod + Pembrolizumab | Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma | Active, not recruiting | USA | 0 |
| NCT05630183 | Phase II | Gemcitabine + Nab-paclitaxel Botensilimab + Gemcitabine + Nab-paclitaxel | A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer | Active, not recruiting | USA | 0 |
| NCT05631574 | Phase I | BMF-219 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer | Terminated | USA | 1 |
| NCT05642949 | Phase Ib/II | MHB036C | Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
| NCT05652855 | Phase Ib/II | MHB088C | Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
| NCT05669482 | Phase Ib/II | Defactinib + Gemcitabine + Nab-paclitaxel + RO5126766 | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (RAMP205) | Active, not recruiting | USA | 0 |
| NCT05720117 | Phase I | PYX-201 | Study of PYX-201 in Solid Tumors | Recruiting | USA | GBR | ESP | BEL | 0 |
| NCT05786924 | Phase Ib/II | BDTX-4933 + Fluorouracil + Irinotecan + Leucovorin + Panitumumab BDTX-4933 + Cetuximab + Fluorouracil + Irinotecan + Leucovorin BDTX-4933 BDTX-4933 + Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab BDTX-4933 + Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin BDTX-4933 + Gemcitabine + Nab-paclitaxel | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | Recruiting | USA | 0 |
| NCT05821556 | Phase II | Capecitabine + Cisplatin + Gemcitabine + Nab-paclitaxel + Simvastatin + Valproic acid Gemcitabine + Nab-paclitaxel + Simvastatin + Valproic acid Gemcitabine + Nab-paclitaxel Capecitabine + Cisplatin + Gemcitabine + Nab-paclitaxel | Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients | Recruiting | ITA | ESP | 0 |
| NCT05846516 | Phase I | ATP162 + Ezabenlimab + VSV-GP154 ATP150 + ATP152 + VSV-GP154 ATP150 + ATP152 + Ezabenlimab + VSV-GP154 | A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer | Active, not recruiting | USA | FRA | ESP | DEU | CHE | 0 |
| NCT05862324 | Phase Ib/II | TAC01-CLDN18.2 | TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (TACTIC-3) | Active, not recruiting | USA | CAN | 0 |
| NCT05875168 | Phase Ib/II | DS-3939a | First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors | Recruiting | USA | FRA | ESP | CAN | BEL | 3 |
| NCT05922930 | Phase Ib/II | TROP2-CAR/IL15-transduced CBNK cells Cyclophosphamide + Fludarabine | Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer | Recruiting | USA | 0 |
| NCT05968326 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Atezolizumab + Autogene cevumeran + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected Pancreatic Ductal Adenocarcinoma (IMCODE003) | Recruiting | USA | SWE | NLD | GBR | FRA | ESP | DEU | CAN | BEL | 1 |
| NCT05969041 | Phase I | MT-302 | Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony) | Recruiting | AUS | 0 |
| NCT05977322 | Phase I | 177Lu-FF58 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | Terminated | NLD | ISR | ESP | CHE | 0 |
| NCT05983133 | Phase I | SGN-EGFRd2 | A Study of SGN-EGFRd2 in Advanced Solid Tumors | Active, not recruiting | USA | GBR | 0 |
| NCT05984602 | Phase I | Canakinumab + Gemcitabine + Nab-paclitaxel + Tislelizumab | A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer | Recruiting | USA | 0 |
| NCT06015724 | Phase II | Daratumumab + Nivolumab + QS21 + TG01 | Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer (DARANIVOVAX) | Recruiting | USA | 0 |
| NCT06024174 | Phase Ib/II | Adagrasib + BBP-398 + Cetuximab Adagrasib + BBP-398 | A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors | Terminated | USA | ISR | FRA | FIN | AUS | 0 |
| NCT06026410 | Phase I | Cabozantinib Cabozantinib + Darlifarnib Adagrasib + Darlifarnib Darlifarnib | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001) | Recruiting | USA | ITA | FRA | ESP | 0 |
| NCT06048484 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Pegfilgrastim AB680 + Etrumadenant + Zimberelimab AB680 + Zimberelimab Zimberelimab | Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma (AIRPanc) | Recruiting | USA | 0 |
| NCT06056323 | Phase Ib/II | HB0045 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | Unknown status | USA | 0 |
| NCT06059001 | Phase I | Gemcitabine + Nab-paclitaxel + OMO-103 | Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC (OMO-103-02) | Active, not recruiting | ESP | 0 |
| NCT06060405 | Phase II | Durvalumab + Oleclumab | Durvalumab and Oleclumab in Resectable PDAC (DORA) | Recruiting | CAN | 0 |
| NCT06069778 | Phase Ib/II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + MVT-5873 + Oxaliplatin | Safety, Tolerability, and Efficacy of mFOLFIRINOX +/- BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma | Terminated | USA | 0 |
| NCT06076837 | Phase I | Balstilimab + Botensilimab + Celecoxib + Chloroquine phosphate + Cisplatin + Gemcitabine + Nab-paclitaxel | The Seven Trial: Exploiting the Unfolded Protein Response | Active, not recruiting | USA | 0 |
| NCT06084481 | Phase I | Itraconazole + Telisotuzumab adizutecan Telisotuzumab adizutecan | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | Active, not recruiting | USA | ISR | ESP | AUS | 4 |
| NCT06105021 | Phase Ib/II | AFNT-211 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | Active, not recruiting | USA | 0 |
| NCT06119217 | Phase II | Gemcitabine + Nab-paclitaxel + TTX-030 Gemcitabine + Nab-paclitaxel Budigalimab + Gemcitabine + Nab-paclitaxel + TTX-030 | Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients | Active, not recruiting | USA | ITA | FRA | ESP | AUS | 2 |
| NCT06131840 | Phase I | Bevacizumab + SGN-CEACAM5C Bevacizumab + Fluorouracil + Leucovorin + SGN-CEACAM5C Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + SGN-CEACAM5C Fluorouracil + Leucovorin + Oxaliplatin + SGN-CEACAM5C SGN-CEACAM5C Fluorouracil + Leucovorin + SGN-CEACAM5C | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | Recruiting | USA | SWE | NLD | GBR | FRA | ESP | CAN | 0 |
| NCT06141031 | Phase Ib/II | TTI-101 | Phase I/IB Trial of Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma | Active, not recruiting | USA | 0 |
| NCT06158139 | Phase I | iC9-CAR.B7-H3 T-cells | Autologous CAR-T Cells Targeting B7-H3 in PDAC | Recruiting | USA | 0 |
| NCT06188702 | Phase Ib/II | S095035 S095035 + TNG462 | S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP | Recruiting | USA | ITA | FRA | ESP | DNK | DEU | AUS | 1 |
| NCT06194877 | Phase I | BGB3245 + Panitumumab | A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers | Terminated | USA | AUS | 0 |
| NCT06203821 | Phase I | NP137 Fluorouracil + Irinotecan + Leucovorin + NP137 + Oxaliplatin | Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer | Not yet recruiting | USA | 0 |
| NCT06205849 | Phase I | JNJ-64457107 | Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer | Recruiting | USA | 0 |
| NCT06206876 | Phase I | FL118 | FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma | Withdrawn | USA | 0 |
| NCT06219941 | Phase II | AZD0901 + Irinotecan AZD0901 + Liposomal irinotecan AZD0901 + Leucovorin AZD0901 + Fluorouracil AZD0901 + Gemcitabine AZD0901 | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | Recruiting | USA | POL | GBR | ESP | CAN | AUS | 8 |
| NCT06242691 | Phase II | MK-1200 | Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors | Completed | USA | ISR | AUS | 3 |
| NCT06255665 | Phase I | JNJ-79032421 | A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors | Completed | ESP | 0 |
| NCT06305247 | Phase Ib/II | IPN01194 | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours | Recruiting | USA | FRA | ESP | 0 |
| NCT06330064 | Phase II | Ifinatamab deruxtecan | A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) | Recruiting | USA | TUR | POL | NLD | ITA | IRL | FRA | ESP | DEU | BRA | BEL | AUS | ARG | 5 |
| NCT06334432 | Phase Ib/II | NUV-1511 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
| NCT06378047 | Phase I | Pembrolizumab | Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer | Completed | USA | 0 |
| NCT06381154 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Pembrolizumab + Verteporfin | Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer | Recruiting | USA | 0 |
| NCT06385925 | Phase Ib/II | Gemcitabine + Nab-paclitaxel + TSN1611 Cetuximab + TSN1611 Fluorouracil + Leucovorin + Oxaliplatin + TSN1611 TSN1611 | A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation | Recruiting | USA | 1 |
| NCT06390059 | Phase II | Atezolizumab + Gemcitabine + Nab-paclitaxel | EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma | Active, not recruiting | ESP | DEU | CZE | CHE | 0 |
| NCT06393400 | Phase I | Fecal microbiota + Gemcitabine + Nab-paclitaxel | CHemotherapy And Stool Transplant in PDAC (CHASe-PDAC) (CHASe-PDAC) | Recruiting | CAN | 0 |
| NCT06398587 | Phase II | Gemcitabine + Nab-paclitaxel + Onvansertib | Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma | Withdrawn | USA | 0 |
| NCT06428409 | Phase Ib/II | Cisplatin + Pembrolizumab + Sacituzumab tirumotecan Fluorouracil + Leucovorin + Sacituzumab tirumotecan Sacituzumab tirumotecan | A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) | Recruiting | USA | TUR | ITA | GBR | ESP | CHE | CAN | AUS | 5 |
| NCT06445062 | Phase Ib/II | Cetuximab + Daraxonrasib + Fluorouracil + Leucovorin + Oxaliplatin Daraxonrasib + Gemcitabine + Nab-paclitaxel Bevacizumab + Daraxonrasib + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Daraxonrasib Bevacizumab + Daraxonrasib + Fluorouracil + Leucovorin + Oxaliplatin | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Recruiting | USA | 0 |
| NCT06447662 | Phase I | PF-07934040 Gemcitabine + Nab-paclitaxel + PF-07934040 Carboplatin + Pembrolizumab + Pemetrexed Disodium + PF-07934040 Pembrolizumab + PF-07934040 Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + PF-07934040 Cetuximab + PF-07934040 Cisplatin + Pembrolizumab + Pemetrexed Disodium + PF-07934040 | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | Recruiting | USA | 2 |
| NCT06451497 | Phase I | ZM008 | Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT06466187 | Phase I | SGN-MesoC2 | A Study of SGN-MesoC2 in Advanced Solid Tumors | Active, not recruiting | USA | CAN | 0 |
| NCT06498518 | Phase II | Gemcitabine + IMM-101 + Pembrolizumab | A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer (PRIMUS006) | Withdrawn | GBR | 0 |
| NCT06528093 | Phase I | BI 765883 + Gemcitabine + Nab-paclitaxel BI 765883 | A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy | Terminated | USA | FRA | ESP | DEU | BEL | 1 |
| NCT06544655 | Phase I | BMS-986484 + Nivolumab BMS-986484 BMS-986484 + Capecitabine + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin | A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors | Recruiting | USA | CAN | AUS | 1 |
| NCT06545942 | Phase I | MOMA-313 + Olaparib MOMA-313 | Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | GBR | ESP | 0 |
| NCT06562192 | Phase I | 177Lu-NNS309 | Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers | Recruiting | USA | NLD | ITA | ISR | FRA | ESP | DEU | CHE | CAN | BEL | 0 |
| NCT06592664 | Phase Ib/II | Gemcitabine + Nab-paclitaxel CEND-1 + Gemcitabine + Nab-paclitaxel | LSTA1 Phase 1b/2a Continuous Infusion Trial in mPDAC (FORTIFIDE) | Withdrawn | 0 | |
| NCT06598007 | Phase Ib/II | CT3001 | A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT06598371 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + KSQ-004EX KSQ-004EX | A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT06599502 | Phase Ib/II | AZD0022 + Cetuximab AZD0022 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01) | Terminated | USA | AUS | 2 |
| NCT06608927 | Phase III | Gemcitabine + Nab-paclitaxel AB680 + Gemcitabine + Nab-paclitaxel | Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PRISM-1) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUT | AUS | 2 |
| NCT06625320 | Phase III | Fluorouracil + Leucovorin + Liposomal irinotecan Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Gemcitabine + Nab-paclitaxel Daraxonrasib | Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | 2 |
| NCT06626256 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin + STIL101 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma | Withdrawn | 0 | |
| NCT06639724 | Phase I | Fostamatinib + Gemcitabine + Nab-paclitaxel | Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer | Recruiting | USA | 0 |
| NCT06648434 | Phase I | ATI-450 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma | Recruiting | USA | 0 |
| NCT06690281 | Phase II | Cyclophosphamide + Fludarabine Aldesleukin + Autologous KRAS mutant TCR-transduced PBLs | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies | Withdrawn | USA | 0 |
| NCT06704724 | Phase I | Cisplatin + Paclitaxel + Pembrolizumab + PF-07985045 PF-07284892 + PF-07985045 Cisplatin + Pembrolizumab + Pemetrexed Disodium + PF-07985045 Carboplatin + Paclitaxel + Pembrolizumab + PF-07985045 Pembrolizumab + PF-07985045 Carboplatin + Pembrolizumab + Pemetrexed Disodium + PF-07985045 Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin + PF-07985045 Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + PF-07985045 PF-06801591 + PF-07985045 Gemcitabine + Nab-paclitaxel + PF-07985045 Cetuximab + PF-07985045 PF-07985045 | A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. | Active, not recruiting | USA | 1 |
| NCT06710132 | Phase Ib/II | M9140 | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | Recruiting | USA | ITA | FRA | ESP | DEU | AUT | AUS | 3 |
| NCT06764771 | Phase I | Adagrasib + BMS-986488 + Cetuximab BMS-986488 + Nivolumab BMS-986488 Adagrasib + BMS-986488 | A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors | Active, not recruiting | USA | CAN | AUS | 0 |
| NCT06790602 | Phase II | Cemiplimab + Gemcitabine | Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (SWITCH) | Recruiting | USA | 0 |
| NCT06804824 | Phase I | Sotorasib + VVD-159642 VVD-159642 Trametinib + VVD-159642 | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
| NCT06813079 | Phase II | Abemaciclib Ceritinib Selinexor Doxorubicin Etoposide Brigatinib Ponatinib Neratinib Cobimetinib | Using Tumor Models to Determine Treatments | Not yet recruiting | CAN | 0 |
| NCT06818812 | Phase I | Gemcitabine + INCB186748 + Nab-paclitaxel Fluorouracil + INCB186748 + Leucovorin + Oxaliplatin Cetuximab + INCB186748 INCB186748 | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Active, not recruiting | USA | 0 |
| NCT06831136 | Phase II | Capecitabine + Pembrolizumab Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Pembrolizumab Cisplatin + Gemcitabine + Nab-paclitaxel + Pembrolizumab Gemcitabine + Nab-paclitaxel + Pembrolizumab Fluorouracil + Leucovorin + Liposomal irinotecan + Oxaliplatin + Pembrolizumab | Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma (PANCARDINAL-2) | Recruiting | USA | 0 |
| NCT06843551 | Phase II | Balstilimab + Botensilimab | The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation (EMPIRE) | Recruiting | USA | 0 |
| NCT06861452 | Phase Ib/II | Gemcitabine + Nab-paclitaxel + RR001 | Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients with Locally Advanced Pancreatic Carcinoma (SNIPER) | Recruiting | ITA | 0 |
| NCT06864169 | Phase II | Raludotatug deruxtecan | A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) (REJOICE-GI01) | Active, not recruiting | USA | FRA | ESP | CHE | CAN | ARG | 4 |
| NCT06882746 | Phase I | BI 765049 | A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas | Recruiting | USA | 0 |
| NCT06885034 | Phase Ib/II | GSK5764227 | A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed | Recruiting | USA | SWE | POL | NOR | NLD | ITA | FRA | ESP | CAN | BRA | BEL | AUS | 2 |
| NCT06921928 | Phase Ib/II | AZD4360 | Study for AZD4360 in Participants With Advanced Solid Tumours | Recruiting | USA | GBR | DEU | 2 |
| NCT06922591 | Phase Ib/II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + TNG462 Gemcitabine + Nab-paclitaxel + TNG462 Daraxonrasib + TNG462 RMC-9805 + TNG462 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | Recruiting | USA | 0 |
| NCT06941857 | Phase II | Fluorouracil + Ipilimumab + Irinotecan + Leucovorin + NC410 + Nivolumab + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + NC410 + Nivolumab + Oxaliplatin | NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer | Recruiting | USA | 0 |
| NCT06943521 | Phase Ib/II | MT-4561 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | Recruiting | USA | 1 |
| NCT06956690 | Phase Ib/II | ENV-501 | A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors | Recruiting | USA | AUS | 0 |
| NCT06974734 | Phase I | PF-08046037 PF-06801591 + PF-08046037 | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies | Active, not recruiting | USA | 1 |
| NCT06981806 | Phase I | Cosibelimab + POL6326 | Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma | Not yet recruiting | USA | 0 |
| NCT06998940 | Phase III | Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel + Panitumumab Fluorouracil + Leucovorin + Liposomal irinotecan + Panitumumab Fluorouracil + Leucovorin + Liposomal irinotecan Fluorouracil + Irinotecan + Leucovorin + Panitumumab | Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | Recruiting | USA | 0 |
| NCT06999187 | Phase I | DR-0202 | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | Recruiting | USA | 0 |
| NCT07020221 | Phase Ib/II | Carboplatin + Pembrolizumab + Pemetrexed Disodium + VS-7375 Gemcitabine + Nab-paclitaxel + VS-7375 Carboplatin + Pembrolizumab + Pemetrexed Disodium VS-7375 Gemcitabine + VS-7375 Cetuximab + VS-7375 | A Phase 1/2a Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | Recruiting | USA | AUS | 0 |
| NCT07021066 | Phase I | BL-M05D1 | Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors | Recruiting | USA | 0 |
| NCT07023731 | Phase Ib/II | ARV-806 | A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation | Recruiting | USA | 0 |
| NCT07024615 | Phase I | ASP2138 Gemcitabine + Nab-paclitaxel Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Capecitabine + Gemcitabine | A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer | Recruiting | USA | 0 |
| NCT07026279 | Phase Ib/II | AMP945 | A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer | Recruiting | USA | AUS | 0 |
| NCT07070232 | Phase Ib/II | BNT327 + YL202 YL202 Itraconazole + YL202 | A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors | Recruiting | USA | ITA | GBR | ESP | DEU | BEL | AUS | 0 |
| NCT07076121 | Phase II | Gemcitabine + Nab-paclitaxel Gemcitabine + MRTX1719 + Nab-paclitaxel | A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | Recruiting | USA | TUR | SWE | SVK | ROU | POL | NLD | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 12 |
| NCT07089940 | Phase I | OMO-103 | OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma | Recruiting | USA | 0 |
| NCT07094113 | Phase I | AMG 410 + Panitumumab AMG 410 AMG 410 + Pembrolizumab | AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS | 1 |
| NCT07094204 | Phase I | ASP5834 ASP5834 + Panitumumab | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors | Recruiting | USA | FRA | ESP | 0 |
| NCT07127874 | Phase I | PHN-012 | A Study of PHN-012 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT07141706 | Phase I | DB-1317 | A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors | Recruiting | USA | AUS | 0 |
| NCT07145255 | Phase Ib/II | MBRC-201 | Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors | Recruiting | USA | 0 |
| NCT07148128 | Phase Ib/II | WEF-001 | Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours. | Recruiting | USA | GBR | CAN | 0 |
| NCT07166601 | Phase I | M0324 + Pembrolizumab Fluorouracil + Irinotecan + Leucovorin + M0324 + Oxaliplatin M0324 | M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors (TITER) | Recruiting | USA | CAN | 1 |
| NCT07186842 | Phase Ib/II | BNT329 | A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 | Recruiting | USA | GBR | ESP | 0 |
| NCT07205718 | Phase Ib/II | TAK-188 | A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors | Recruiting | USA | 0 |
| NCT07207707 | Phase I | KQB548 | A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies | Recruiting | USA | 0 |
| NCT07214298 | Phase Ib/II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Pegcetacoplan | Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | Recruiting | USA | 0 |
| NCT07227168 | Phase I | Pembrolizumab + STRO-004 STRO-004 | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | Recruiting | USA | 0 |
| NCT07252232 | Phase III | Daraxonrasib | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 304) | Recruiting | USA | 1 |
| NCT07252479 | Phase I | AN9025 | Evaluation of a Rat Sarcoma Oncogene (RAS) Inhibitor in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations | Recruiting | USA | 0 |
| NCT07259317 | Phase II | Gemcitabine + Nab-paclitaxel + Relacorilant | Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma | Recruiting | USA | 0 |
| NCT07261631 | Phase I | 177Lu-DFC413 | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors | Recruiting | ISR | FRA | CAN | 1 |
| NCT07280377 | Phase Ib/II | Atezolizumab + Pelareorep Atezolizumab + Pelareorep + Trifluridine-tipiracil hydrochloride Atezolizumab + Gemcitabine + Nab-paclitaxel + Pelareorep Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Pelareorep Atezolizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Pelareorep | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab (GOBLET) | Recruiting | DEU | 0 |
| NCT07283705 | Phase II | MRTX1719 Gemcitabine + MRTX1719 + Nab-paclitaxel Fluorouracil + Irinotecan + MRTX1719 + Oxaliplatin | A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer | Suspended | USA | 0 |
| NCT07311603 | Phase I | M7437 | Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors | Not yet recruiting | DEU | 0 |
| NCT07348107 | Phase I | Arsenic trioxide + Gemcitabine + Nab-paclitaxel + Tislelizumab + Tretinoin | ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma. (ATARI-PDAC) | Not yet recruiting | CAN | 0 |
| NCT07360314 | Phase I | M7437 | Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors | Recruiting | USA | ESP | CAN | 1 |
| NCT07377526 | Phase Ib/II | TROP2 CAR/IL-15 TGFBR2 KO NK cells | Phase 1/2 Study TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer | Not yet recruiting | USA | 0 |
| NCT07450859 | Phase II | BT5528 | A Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Recruiting | USA | 0 |
| NCT07454642 | Phase I | AVA6103 | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors | Recruiting | USA | 0 |
| NCT07483983 | Phase II | ASP3082 | Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK ASP3082) | Not yet recruiting | FRA | 0 |